Myron Schwartz

机构：Mount Sinai Hospital, Sinai Health System, Icahn School of Medicine at Mount Sinai · ORCID：0000-0002-9113-886X

发表论文 531 篇 · 总被引 51712 次 · h-index 101

代表论文

• Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024 · Nature Reviews Clinical Oncology · 被引 359)
• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment (2025 · The Lancet · 被引 164)
• Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study (2024 · Journal of Hepatology · 被引 78)
• A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis (2024 · Gastroenterology · 被引 77)
• Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis (2024 · Gastroenterology · 被引 23)
• Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors (2024 · BJC Reports · 被引 14)